Portfolio Lab

Abivax S.A.

  • Stock
  • Ticker ABVX
  • ISIN US00370M1036
  • Nasdaq
  • US listing in dollars (ADR)

Health care · Pharmaceuticals · France

$73.20 −9.24%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Abivax S.A. since 10/2023, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

ABVXGlobal equities (VT)

$10,000 grew to $72,118. Global equities (VT): $15,235.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −67.5% in 04/2025, measured from the peak in 04/2024. It took 15 months to get back to the old peak.

1-year return
−40.4%
Return p.a. since 10/2023
+102.5%
Volatility p.a.
479.4%
Largest decline
−67.5%

Financial statements

Amounts in € millions from the company's annual financial reports, earnings per share in € per ordinary share

Fiscal year2022202320242025
Income statement
Operating income-65-127-173-246
EBITDA-64-127-172-245
Net income-61-148-176-336
Earnings per share-3.18-3.43-2.80-4.83
Balance sheet
Total assets76327205584
Liabilities68131165129
Equity7.219641455
Cash27252144517
Cash flow
Operating cash flow-54-97-154-161
Capital expenditure-0.3-0.3-0.6-0.1
Free cash flow-54-97-155-161

Annual returns

Best year 2025 at +1,742.3%, weakest 2024 at −31.6%. 1 of 2 full years were positive. * partial year.

Key metrics

Key figures as of 21 Nov 2026 from the company's latest annual financial report, amounts converted to US dollars at the ECB reference rate. Valuation and market cap appear only where price and earnings per share reliably refer to the same share.

Valuation

Market cap
€5.2bn
Market cap in trading currency
$5.70bn
Enterprise value
$5.13bn
P/E
–
P/S
–
P/B
11.39
EV/Sales
–
EV/EBITDA
–
Earnings yield
–
FCF yield
-3.1%

Results (latest fiscal year)

Revenue
–
Gross profit
–
EBITDA
−$269m
Net income
−$369m
Earnings per share
−$5.31
Revenue growth
–
Earnings growth
–

Profitability

Gross margin
–
Operating margin
–
Net margin
–
Return on equity
-135.6%
Return on assets
-57.5%

Balance sheet and cash flow

Cash
$568m
Financial debt
–
Debt/equity %
–
Current ratio
8.75
Book value per share
$7.19
Operating cash flow
−$177m
Free cash flow
−$177m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
69.6m
Volume
14.8m
Avg. volume 3 months
1.35m
Relative volume
13.1

Price and technicals

Price
$73.20
1 day
−9.2%
52-week high
$145.31
52-week low
$72.50
Distance to 52-week high
−49.6%
Distance to 52-week low
+1.0%
Distance to 50-day line
−19.7%
Distance to 200-day line
−34.5%
RSI (14)
30
Volatility 1M
54.7%

Performance

1 week
−16.4%
1 month
−18.9%
3 months
−37.0%
6 months
−40.0%
YTD
−45.7%
1 year
−35.2%

Dates

Fiscal year end
31 Dec 2025

Frequently asked questions

How has ABVX performed since 10/2023?

$10,000 grew to $88,193 by 20 Nov 2026, which is +102.5% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is ABVX?

Volatility was 479.4% per year, measured on monthly returns. The largest decline from a peak was −67.5%, with the low in 04/2025.

How does ABVX compare with a broad equity ETF?

Over the same period Global equities (VT) returned +17.7% per year at 12.8% volatility, ABVX returned +102.5% at 479.4%. The correlation of monthly returns was 0.01; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Why does this page show a US listing?

The figures use the stock's depositary receipt (ADR) traded in the US. On individual days its path differs slightly from the price on the home exchange.

Not investment advice. Key figures and financial statements calculated from the company's annual financial reports, without guarantee; key figures converted to US dollars at the ECB reference rate, statements in the currency of the report.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Abivax S.A. (ABVX): Return and risk | Portfolio Lab